Get instant savings up to 75%
Download the Free PrescriptionDrugs.com Discount Drug Card
Redeem for instant savings up to 75% on name brand
& generic prescription drugs
Accepted at over 60,000 pharmacies nationwide
The FDA has released information about prescription drugs for hepatitis C. The U.S. Food and Drug Administration has approved Victrelis (boceprevir) for the treatment of adults who suffer from chronic hepatitis C.
The FDA has approved the prescription drug Victrelis for usage with standard hepatitis C treatments. Hepatitis C is an infectious disease that attacks the liver. Many people remain asymptomatic, which makes treating the disease more difficult once it is discovered and properly diagnosed. This newly approved therapy is part of the protease inhibitors class of prescription drugs that work by attaching itself to the virus to prevent it from multiplying and spreading.
Victrelis has been approved to help people with Hepatitus C
“Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment” according to an FDA press release.
The approval of Victrelis was based on two separate clinical studies that included 1,500 patients with hepatitis C. Reports showed that in two-thirds of the patients taking Victrelis – combined with two other standard hepatitis C drugs – the virus was undetectable 24 weeks after the treatment had ended.
“Victrelis is an important new advance for patients with hepatitis C. This new medication provides an effective treatment for a serious disease, and offers a greater chance of cure for some patients’ hepatitis C infection compared to currently available therapy” said Edward Cox, MD, MPH. Cox is the Director of the Office of Antimicrobial Products in the Center for Drug Evaluation and Research at the FDA.
For more information about prescription drugs for hepatitis C, visit the FDA website.